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Abstract
Tumor necrosis factor–related apoptosis- inducing li-
gand (TRAIL) induces apoptosis in a variety of trans-
formed cell lines, but generally spares most normal
cells. Transduction by an adenoviral vector expressing
human TRAIL cDNA (Ad.TRAIL-GFP) resulted in both
direct tumor cell killing as well as a potent bystander
effect through presentation of TRAIL by transduced
normal cells. Administration of Ad.TRAIL-GFP signifi-
cantly prolonged survival of mice harboring either
intracerebral glioblastomas or breast carcinoma–in-
duced peritoneal carcinomatosis. Additionally, TRAIL
induced prolonged transgene expression in normal
tissue, presumably as a result of diminished immune-
mediated destruction of vector- transduced cells. Taken
together, these data suggest that vector -mediated
transduction of TRAIL may represent an effective
strategy for cancer gene therapy.
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Introduction
Apoptosis is a genetically encoded cell death program
involving the interaction between multiple regulators [1 ].
Tumor cells may acquire a survival advantage by deregulat-
ing apoptosis through a number of mechanisms including p53
inactivation and/or induction of the bcl -2 pathway. Multi-
cellular organisms have developed innate mechanisms,
some of which involve the induction of apoptosis, for
eradicating virally infected and transformed cells. One
recently elucidated apoptosis pathway involves tumor
necrosis factor–related apoptosis- inducing ligand (TRAIL),
a transmembrane protein of tumor necrosis factor (TNF)
family. Recent evidence suggests that TRAIL has selective
ability to induce apoptosis in various tumor cell lines
compared to normal cells [2–7]. Systemic injection of a
recombinant soluble TRAIL molecule mediated antitumor
activity in tumor-bearing mice, whereas little systemic
toxicity was seen in mice or monkeys following administration
of equivalent doses of the protein [4,5 ]. Although the tumor
selectivity of TRAIL has recently been questioned following
demonstration of TRAIL-mediated cytotoxicity toward
human hepatocytes and astrocytes [8,9 ], these observations
have been attributed to a nonspecific effect of the recombi-
nant protein preparation rather than the TRAIL molecule itself
[10,11]. Despite the promising preliminary data, however,
recombinant soluble TRAIL may pose several limitations as a
therapeutic agent for routine clinical use secondary to the
pharmacologic instability of systemically delivered proteins,
problematic distribution kinetics, and the requirement for large
amounts of expensive- to-produce recombinant protein.
Replication-deficient, recombinant adenoviral vectors are
theoretically attractive gene transfer vehicles due to their
ability to transduce a wide variety of cell types and mediate
high- level transgene expression. We and others have
demonstrated the potential for locally administered adeno-
viral vectors to produce high local concentrations of bio-
logically active proteins in vivo, thereby overcoming the
potential pharmacologic difficulties associated with systemic
protein administration [12,13]. The clinical utility of adenovi-
rus as a gene delivery vehicle, however, may be significantly
limited by undesirable host immune responses directed
toward the virus and vector - transduced cells. We now
demonstrate that adenoviral vector–mediated transfer of a
TRAIL cDNA results in significant antitumor and bystander
effects in vitro and in vivo, without normal tissue toxicity.
Furthermore, we demonstrate that vector -encoded TRAIL
allows prolongation of adenoviral -mediated transgene
expression in normal tissues by delaying death of vector-
transduced cells. Our results support a potential role of TRAIL
cDNA transfer as an effective local antitumor strategy.
Materials and Methods
Cell lines and animals
The human umbilical vein endothelial cells (HUVECs),
U87MG, T98 (human glioblastoma cells ), 293 (human
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embryonic kidney cells ), Colo-205 (human colon carci-
noma), Ramos (Burkitt lymphoma), and IMR90 (human
primary fibroblast cells ) were purchased from American
Type Culture Collection (ATCC, Rockville, MD). TA3, a
mouse mammary ascites tumor cell line was kindly provided
by H. F. Dvorak (Beth Israel Hospital, Boston, MA). Human
primary astrocytes (NHAs) and human fetal neural progen-
itor (HNP) cells were purchased from Clonetics (San Diego,
CA). NHAs and HNP cells were cultured according to the
manufacturer’s protocol. HUVECs were cultured in Medium
199 supplemented with 10% fetal bovine serum (FBS), 100
g/ml heparin and 30 g/ml endothelial growth factor
(Sigma, St. Louis, MO). Ramos and Colo-205 were
maintained in RPMI medium supplemented with 10% FBS.
All other cells were maintained in Dulbecco’s modified
Eagle’s medium (Life Technologies, Grand Island, NY)
supplemented with 10% FBS. Four- to six-week-old nude
mice (Ncr-nufBR) and Swiss Webster mice were obtained
from Taconic (Germantown, NY). Animal studies were done
in accordance with guidelines of the Animal Care and Use
Committee.
Recombinant Adenoviral Vectors
Human TRAIL cDNA was cloned from human fetal brain
cDNA library (Clontech, Palo Alto, CA) by PCR using
two oligonucleotide primers 50 -CTGAGCGGCCGCAGTCA-
GACTCTGACAGGAT-30 and 50 -TGAGGCGGCGGCCG-
CTTTTTCTTTCCAGGTCAGT-30. Amplified TRAIL cDNA
fragment was inserted into the NotI site of a shuttle plasmid
to generate the pTRACK-CMV-TRAIL vector. Transcription
of the TRAIL gene was driven by the cytomegalovirus (CMV)
enhancer /promoter, terminated with the SV40 poly-A
signal. This shuttle vector also contains the green fluores-
cent protein (GFP) gene, expression of which was useful as
a marker for monitoring efficiency of transfection. Control
pTRACK-CMV-GFP vector only carries the GFP gene
(kindly provided by B. Vogelstein, Johns Hopkins Univer-
sity ). The construction of the recombinant adenoviral vectors
Ad.TRAIL-GFP and Ad.GFP followed the protocol described
previously [14]. Briefly, a pTRACK-CMV-TRAIL and a
backbone plasmid containing the genome of Ad5 with
deletions in the E1 and E3 regions (pAdEasy-1) were
cotransformed into BJ 5183, a recombination-permissive E.
coli strain, for isolation of a pro-adenoviral plasmid. The
structure of the resultant recombinant vectors were con-
firmed by restriction enzyme digestion (BamHI and Not I )
and DNA sequencing. Thirty micrograms of proviral DNA
was used in transfecting 293 cells by standard calcium
phosphate coprecipitation method. Approximately 7 to 10
days later, virus plaques were observed and the recombinant
viruses were further propagated in 293 cells as previously
described [15]. The virus stocks were purified by two rounds
of cesium chloride–gradient ultracentrifugations, dialyzed
against 10% glycerol, 10 mM Tris (pH 8.0) and 1 mMMgCl2,
and stored at 808C. Virus titers were determined as
plaque- forming units (PFU) assay and GFP-expressing
units assay in 293 cells. Typical viral titers obtained were
around 51010 to 51011 PFU/ml.
Western Blot Analysis
Western blot analysis was performed by using anti -TRAIL
antibody (C-19, Santa Cruz Biotechnology, Santa Cruz,
CA), anti -GFP antibody (clone 11E5, Quantum Biotech-
nology, Montreal, Canada), anti -TuJ1 antibody (Babco,
Richmond, CA), antitubulin and anti -PARP antibody (Phar-
mingen, Franklin Lakes, NJ), followed by a secondary pero-
xidase antibody (Santa Cruz Biotechnology).
RT-PCR Analysis
Reverse transcription polymerase chain reaction (RT-
PCR) was performed using a standard protocol and PCR
primer sequences that are described elsewhere [16].
In Situ Apoptotic Cell Detection Assay
Terminal transferase-mediated dUTP nick end labeling
(TUNEL) assay was performed on paraffin-embedded and
frozen tissue sections, according to the protocol recom-
mended by the supplier ( Intergen, Purchase, NY). 3,30 -
Diaminobenzidine (DAB) substrate (Vector Laboratories,
Burlingame, CA) and rhodamine-conjugated antidigoxyge-
nin antibody were used for visualization.
TRAIL Cytotoxicity Assay
Cells were plated into six-well plates at 105 cells per well
in triplicate. Target cells transduced by either Ad.TRAIL-
GFP or Ad.GFP (multiplicity of infection, MOI=10 to 200
depending on the cell type) were incubated for 48 to 72 hours
and prepared for fluorescence-activated cell sorting (FACS)
analysis to determine the apoptotic index. For coculture
experiments, effector cells were infected with either
Ad.TRAIL-GFP or Ad.GFP and target cells were infected
with Ad.CMV-gal. One day later, both cell populations were
replated and mixed. After incubation for 48 to 72 hours,
cocultured cells were processed for  -gal (5-bromo-
4-chloro-3- indolyl - -D-galactopyranoside) staining in a
solution containing 5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6,
and 1 mg/ml  -gal (5-bromo-4-chloro-3- indolyl - -D-
galactopyranoside). Survival of target cells was quantified
by counting the stained cells per randomly chosen200 field.
Neural Progenitor Cell Coculture
HNP cells were cultured in B27 media with basic fibroblast
growth factor (50 ng/ml) and epidermal growth factor
(50 ng/ml) [17]. HNP cells were infected either with Ad.GFP
or Ad.TRAIL-GFP (MOI=50) Nearly 100% of cells were
infected. Neuronal differentiation was induced by removal of
growth factors for 10 days on poly-ornithine–coated slides.
For coculture, infected HNP (105) and uninfected U87 MG
cells (105) were cocultured for additional 2 days and TUNEL
assay was performed.
Intracerebral Tumor Model
U87 MG cells (106) were resuspended in 5 l of Hank’s
balanced salt solution (HBSS) and injected into the right
caudate nucleus (1 mm posterior to the bregma and 2 mm
lateral to the midline) using a small animal stereotactic frame
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(Kopf Instruments, Tujunga, CA). Five days after tumor
implantation, either Ad.TRAIL-GFP or Ad.GFP (5108
PFU) ( in 5 l HBSS) was injected into the established
tumors using the same stereotactic coordinates. Non–tumor
bearing mice were treated with 5108 PFU virus for
evaluation of Ad.TRAIL-GFP–mediated neurotoxicity.
Intraperitoneal Ascites Tumor Model
TA3 cells (106) were resuspended in 200 l of HBSS and
injected in the peritoneal cavity of male nude mice. On days
0, 4, and 8, animals received intrapertoneal doses of either
Ad.TRAIL-GFP or Ad.GFP (109 PFU). Animals were
monitored daily for ascites formation and survival. Autopsies
Figure 1. Induction of apoptosis in tumor cells by Ad.TRAIL -GFP vector. (A ) Structure of Ad.TRAIL -GFP and Ad.GFP. The adenoviral sequences E1 and E3 are
deleted. Ad.TRAIL -GFP vector expresses both TRAIL and GFP. (B ) Western blot analysis of Ad.GFP - or Ad.TRAIL -GFP– transduced IMR90 cells or U87 glioma
cells using an anti -TRAIL antibody ( top ), an anti -PARP antibody (middle ), an antitubulin antibody ( bottom), respectively. (C ) Apoptotic index of cells (U87, T98,
HUVEC, IMR90, NHA [MOI 100 ], and TA3 [MOI 50 ] ) infected with Ad.TRAIL -GFP or Ad.GFP. Statistical significance between treatment was evaluated by
Student’s t test ( asterisk: P<0.01 ). (D ) Expression of four TRAIL receptors in a panel of cell lines, as determined by semiquantitative RT-PCR.
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were performed on all mice to determine tumor burden and
ascites volume. Statistical significance of survival between
different groups was assessed by log-rank analysis of
Kaplan-Meier curves.
Duration of Transgene Expression
Either Ad.TRAIL-GFP or Ad.GFP (1010 PFU) was
injected into tail veins of immunocompetent Swiss Webster
mice (Taconic ). Animals were killed 4, 7, 14, and 30 days
later. Liver tissue was obtained and processed for cryosec-
tion and protein extraction.
Tissue Preparation
Brain and tumor tissues were harvested and fixed in 4%
paraformaldehyde/PBS overnight, and then washed in 30%
sucrose in PBS. Brains were cut coronally along the needle
track and slices were used for paraffin section or embedded
in O.C.T. compound (Tissue Tek, Germantown, NY) for
cryosection.
Results
Biological Activity of Vector -Transduced TRAIL In Vitro
Previous reports have demonstrated minimal activity of
monomeric soluble TRAIL recombinant protein, with signifi-
cant increases in activity seen following TRAIL oligomeriza-
tion [16,18]. Because TRAIL exists mainly as a cell -surface
protein in vivo, we hypothesized that cell -associated TRAIL
might be more active than soluble TRAIL and therefore we
Figure 2. TRAIL -mediated cell killing in cocultures. (A ) Human fibroblasts ( IMR90 ) were infected with Ad.GFP or Ad.TRAIL -GFP (MOI 100 ) and cocultured with
target cells for 3 days. Representative photographs (400 ) of Colo - 205 and Ramos cells after 3 days of coculture. (B ) Viability of tumor cells after coculture with
different effector cells expressing TRAIL. All target cells were infected with Ad.gal (MOI 100 ) 1 day before coculture and then applied to each well. The number of
gal - positive cells in randomly chosen fields ( four per group ) were counted 3 days later. Relative survival (% ) in Ad.TRAIL -GFP coculture was normalized to the
control (Ad.GFP ) and statistical significance between treatment was evaluated by Student’s t test ( asterisk: P<0.01 ). (C ) Representative photographs of coculture
of TA3 cells and IMR 90 cells were shown.
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constructed an adenovirus vector carrying a transmembrane
form of a human TRAIL cDNA under the control of the CMV
early promoter (Figure 1A ). Western blot analysis from cells
transduced by Ad.TRAIL-GFP revealed a strong immunor-
eactive protein of32 kDa consistent with a transmembrane
form of TRAIL (Figure 1B ). To assess biologic activity of the
vector-expressed TRAIL, several tumor cell lines and human
primary cells were directly infected with either Ad.TRAIL-
GFP or Ad.GFP, cultured for 2 days and assayed for
apoptotic cell death. Using anMOI of 100, >95% of cells were
GFP-positive assuring high vector - transduction efficiency.
Transduction by Ad.TRAIL-GFP induced apoptosis in 40%
of U87 human glioma cells, 20% of T98 human glioma cells,
and 22% of TA3 mouse mammary carcinoma–transduced
cells (Figure 1C ). In contrast, human primary endothelial
cells (HUVECs) and human fibroblast ( IMR90) and, most
importantly, NHA infected with Ad.TRAIL-GFP showed no
increase in apoptosis compared to those infected with
Figure 3. Evaluation of neurotoxic effects of Ad.TRAIL -GFP. (A ) HNP cells transduced in vitro with Ad.GFP or Ad.TRAIL -GFP and then induced to differentiate
along neuronal ( TuJ1+ ) lines (difference between number of TuJ1+ cells following Ad.GFP or Ad.TRAIL -GFP transduction of HNP not significant; P > 0.4 ). (B )
HNP cells transduced with Ad.GFP or Ad.TRAIL -GFP and coculture with U87 glioma cells. HNP and U87 cells were visualized by DAPI staining and GFP positive
cells were HNP cells. White arrows demonstrate apoptotic cells immediately adjacent to Ad.TRAIL -GFP– transduced HNP cells. Difference between number of
apoptotic U87 target cells exposed versus Ad.TRAIL -GFP– transduced HNP cells highly significant (P<0.001 ). (C ) Two days following the injection of Ad.TRAIL -
GFP (5108 PFU) into the brains of non– tumor -bearing mice, brains were obtained and prepared for histology and TUNEL assay. Representative photographs
(200 ) of brain sections stained with H&E (upper panel ); representative photographs (200 ) of brain frozen section stained for apoptotic cells ( lower panel ).
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Ad.GFP (Figure 1C ). Western blots of the Ad.TRAIL–
transduced U87 tumor cells, but not normal cells, demon-
strated the appearance of the characteristic 115- and 85-
kDa PARP doublet consistent with a TRAIL-mediated
apoptotic mechanism of cell death (Figure 1B ). Although
we detected TRAIL type 2 (R2) and decoy type 1 (D1)
receptor mRNA by semiquantitative RT-PCR in all of our cell
lines, we, like other investigators, were unable to correlate
receptor type expression with sensitivity to TRAIL-mediated
cytotoxicity (Figure 1D ).
Adenoviral vectors infect both dividing and nondividing
cells. Because our preliminary results suggest that normal
primary cells including endothelial cells, astrocytes, and
fibroblasts were insensitive to Ad.TRAIL-GFP (Figure 2A ),
we hypothesized that these transduced normal cells might
be capable of ‘‘presenting’’ membrane-associated TRAIL
to neighboring tumor cells. Although NHA and endothelial
cells effectively expressed TRAIL following vector trans-
duction (data not shown), we chose to use the transduced
IMR90 cells for the coculture experiments because these
cells, unlike the other normal cell types, grow in a basic
defined media, thereby simplifying the conditions for the
coculture experiments. Thus, Ad.TRAIL-GFP–transduced
IMR90 cells were cocultured with several different lympho-
cytic cell lines. Unlike IMR90, these cells grow in
suspension, which facilitated easy distinction between cell
types. Colo-205 and Ramos cells grew normally after 3
days of coculture with Ad.GFP- infected IMR90 cells. In
contrast, few cells survived in coculture with Ad.TRAIL-
GFP–infected IMR90 cells. There was no difference in
IMR90 cell survival in either group (Figure 2A ). To
evaluate whether TRAIL- infected IMR90 cells could also
mediate cytotoxicity against cocultured adherent tumor cell
lines, TA3 and U87 cells were first infected with Ad.gal as
a target cell marker and then cocultured with Ad.TRAIL-
GFP–transduced IMR90 cells. As shown in Figure
2;B and C, greater than 70% and 95% of cocultured U87
and TA3 cells were killed, respectively.
Because we were unable to kill all of the tumor cells by
direct infection with Ad.TRAIL-GFP (Figure 1C ), we
wondered whether the surviving infected tumor cells could
function as ‘‘effector’’ cells and kill uninfected tumor cells.
Ad.TRAIL-GFP–transduced U87 cells that survived the
initial infection were used as ‘‘effector’’ cells, whereas
 -galactosidase–transduced U87 and T98 cells were used
as targets in this coculture experiment. Although less
effective than IMR90 effector cells, Ad.TRAIL-GFP–
transduced U87 cells were capable of eliminating >30% of
the uninfected tumor cells (Figure 2B ). By contrast,
conditioned media from Ad.TRAIL-GFP–transduced normal
and tumor cells did not induce apoptosis in target cells
arguing against the possibility of a biologically active secreted
TRAIL molecule as the mediator of cell death (data not
shown).
Vector-Transduced TRAIL-Mediated Cytotoxicity In Vivo
A main concern for exogenous expression of TRAIL in
vivo is potential normal tissue toxicity. Indeed, two recent
reports suggest that human primary astrocytes and hepato-
cytes in vitro were susceptible to recombinant TRAIL-
mediated death in vitro, although in vivo systemic delivery
of recombinant TRAIL did not cause detectable toxicity in the
hands of several different investigators [5,8,9 ]. Recent
reports have suggested that such effects were related to
Figure 3. (continued )
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nonspecific toxicities of the specific protein preparation that
was used for the in vitro experiments [10,11]; however, the
potential for neurotoxicity remained a major concern for us.
It was, therefore, encouraging to us that transduction of
NHA by Ad.TRAIL-GFP did not induce cytotoxic effects in
vitro (Figure 1C ). Nevertheless, it is still possible that
neuronal or non-astrocytic glia might be sensitive to
TRAIL, a phenomenon that may not have been seen
following systemic injection of recombinant TRAIL secon-
dary to the exclusion of the protein from the central
nervous system by the blood–brain barrier. To address the
potential for Ad.TRAIL-GFP–mediated neural toxicity,
we transduced HNP cells with adenoviral vectors express-
ing either GFP or TRAIL and then differentiated toward
a neuronal lineage. As demonstrated in Figure 3A, TRAIL-
infected HNP cells survived and differentiated normally
compared to GFP- infected and parental HNP cells, yet
were still capable of presenting biologically active TRAIL
molecules and mediate a potent bystander effect against
U87 glioma cells (Figure 3B ). Additionally, we evaluated the
acute and chronic affects of TRAIL expression in normal
mouse brain by stereotactically injecting Ad.TRAIL-GFP
(5108 PFU) into the caudate nucleus. There were no
clinical or histopathologic signs of increased inflammation or
apoptosis in the Ad.TRAIL-GFP–injected brains compared
to Ad.GFP- injected brains at 2 and 4 days following the
injection of the vector (Figure 3C ). Animals were monitored
for an additional 2 months, with no detectable clinical or
histologic abnormality outside of the usual, mostly monocytic
infiltration seen following the injection of any adenoviral
vector into the brain [19]. In addition, intraperitoneal injection
of Ad.TRAIL-GFP vector into non–tumor-bearing immuno-
deficient mice did not induce gross or histologically evident
systemic toxicity compared to that seen with control
adenoviral vectors (data not shown).
To assess the in vivo antitumor activity of Ad.TRAIL-
GFP, we used both a human glioblastoma orthotopic
xenograft and a mouse mammary peritoneal carcinomatosis
model. For the glioblastoma model, U87 cells were
stereotactically implanted intracerebrally followed by injec-
tion of Ad.TRAIL-GFP or Ad.GFP into the growing tumor 5
days later using the same initial stereotactic coordinates.
Animals were then followed for survival. As can be seen in
Figure 4A, Ad.TRAIL-GFP–treated animals survived sig-
nificantly longer than control treated animals (P<0.001, log
rank analysis). Likewise, to evaluate the antitumor effect of
Ad.TRAIL-GFP on nude mice bearing intraperitoneal,
malignant ascites tumors, animals with established TA3
intraperitoneal mammary carcinomas were given three
separate intraperitoneal injections of Ad.TRAIL-GFP or
Ad.GFP. As shown in Figure 4B, animals treated with
Ad.TRAIL-GFP survived significantly longer than those
treated with the control virus (P<0.001). TUNEL staining
on brain tumor sections from Ad.TRAIL-GFP–treated intra-
cerebral U87 tumor-bearing mice demonstrated a signifi-
cantly elevated level of tumor cell apoptosis compared
to brain tumors from control vector- treated animals
(Figure 4C ).
Figure 4. In vivo antitumor activity of Ad.TRAIL -GFP. (A ) Kaplan -Meier survival curves of animals treated by stereotactic injection of viral vectors into
preestablished U87 gliomas. (B ) Kaplan -Meier survival curves of TA3 ascites tumor - bearing mice treated by intraperitoneal injection of Ad.GFP (open square ) or
Ad.TRAIL -GFP (closed square ). Survival is significantly prolonged by log rank analysis (P<0.001 ). (C ) representative photographs of brain frozen section stained
for apoptotic cells. Arrows indicate TUNEL -positive cells.
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Duration of Ad.TRAIL-GFP Transgene Expression In Vivo
A major limitation to the use of adenoviral vectors for in
vivo gene transfer is the loss of transgene expression due to
the immune-mediated elimination of virally transduced cells,
although prolonged transgene expression is observed in
immune privileged sites such as the brain, cornea, and testis
[19-21]. FasL, a transmembrane protein belonging to the
TNF family, has been shown to be responsible for maintain-
ing immune privileged status in these sites [20,21]. There-
fore, we hypothesized that exogenous expression of TRAIL
from adenoviral transduced cells might create a situation
analogous to the immune-privileged microenvironment,
thereby facilitating prolonged transgene expression. To
evaluate whether Ad.TRAIL-GFP–transduced cells could
prolong the duration of expression from a coexpressed
transgene in the liver of immunocompetent mice, Ad.TRAIL-
GFP or Ad.GFP was injected through the tail vein. Following
a single intravenous injection of Ad.GFP, we found GFP
transgene expression in the liver at day 4, with rapid
disappearance by day 7. In contrast, GFP expression was
seen for >30 days in Ad.TRAIL-GFP–infected liver (Figure
5A ). Western blot analysis confirmed significantly prolonged
duration of hepatic GFP expression in the Ad.TRAIL-GFP–
injected animals (Figure 5B ). We observed substantially
fewer inflammatory cells in the Ad.TRAIL-GFP–transduced
livers compared to the Ad.GFP-transduced livers (data not
shown). Additionally, there were significantly fewer numbers
of apoptotic hepatocytes seen in the Ad.TRAIL-GFP
transduced livers compared to the Ad.GFP control vector-
transduced livers at day 7 (Figure 5;C and D ). These
Figure 5. Duration of GFP transgene expression in the liver following injection of Ad.TRAIL -GFP. Immunocompetent mice were given Ad.GFP or Ad.TRAIL -GFP
(1010 PFU ) through the tail vein. (A ) On days 4, 7, 14, and 30, the liver was examined for GFP fluorescence. Representative photographs (400 ) of unfixed
cryosection. (B ) Western blot analysis from livers infected with Ad.TRAIL -GFP or Ad.GFP. A single 28 - kDa band corresponding to the size of GFP protein
( arrow ) was detected. (C ) Increased apoptotic index in Ad.GFP - infected liver compared with Ad.TRAIL -GFP– infected liver 7 days after intravenous injection of
virus. (D ) Quantitative summary of the apoptotic index from vector - transduced livers (asterisk: P<0.01 ).
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observations are consistent with a diminished inflammatory
cell -mediated anti -adenoviral response directed against the
Ad.TRAIL-GFP–transduced hepatocytes compared to the
Ad.GFP-transduced hepatocytes.
Discussion
TNF family members such as TNF and FasL have significant
and potent antitumor activity in vitro and in vivo; however,
their clinical utility has been hampered by severe local and
systemic toxicity. TRAIL has been recognized as a poten-
tially promising new tool for cancer gene therapy given its
ability to induce apoptosis in a variety of transformed cell
lines, with few adverse effects on most normal cells in vitro.
TRAIL mRNA is widely expressed in most human tissues at
significant levels [2 ]. To date, five TRAIL-binding receptors
(TRAIL-R1 to TRAIL-R4, and osteoprotegerin ) have been
identified [22-24]. TRAIL-R1 and TRAIL-R2 are able to
induce apoptosis by engaging TRAIL, whereas, TRAIL-R3
and TRAIL-R4 are incapable of transducing death signal due
to deletion or truncation of its cytoplasmic domain, respec-
tively. Curiously, however, expression patterns of different
TRAIL receptors in a variety of cell types do not appear to
closely correlate with sensitivity to TRAIL. Although the
tumor-specific mechanism of TRAIL and its physiological
role remain to be elucidated, it is interesting to note that
TRAIL-mediated cell killing does not seem to depend on the
p53 status of the cell [24]. This makes TRAIL even more
attractive as a potential antitumor agent given the frequency
with which p53 is mutated in human cancer.
Like other TNF family members, TRAIL exists as a type 2
transmembrane protein, which can be cleaved by specific
proteases to a soluble form [25]. Although soluble TNF
maintains high biologic activity, both FasL and TRAIL lose
significant activity as soluble monomeric proteins. More
active forms of soluble TRAIL can be generated, however, by
inducing oligomerization of the monomers through genetic,
biochemical, or antibody-mediated approaches [26-28].
These large multimeric proteins may, however, present
difficult clinical drug delivery challenges particularly for
tumors of the central nervous system, where an even
partially intact blood–brain barrier is likely to limit efficient
systemic delivery of such molecules.
We and others have previously demonstrated the ability of
stereotactically injected adenoviral vectors to efficiently
transduce relatively large areas of the brain, thereby creating
a zone of high transgene protein expression [15,19]. Thus,
we hypothesized that TRAIL represented a potentially
promising transgene for adenoviral transduction given its
tumor-selective cytotoxic profile. A transgene encoding a
soluble TRAIL protein, however, would result in a relatively
inactive protein. Although we considered constructing
adenoviral vectors that encode TRAIL proteins that might
spontaneously aggregate ( i.e., TRAIL mutants with leucine
zippers) [5 ], it seemed problematic that such aggregation
would occur spontaneously and efficiently following trans-
gene delivery in vivo. Thus, given the fact that TRAIL
naturally exists as a transmembrane protein, we elected to
create vectors that encode a transmembrane form of TRAIL.
Our data suggest that transmembrane expression is indeed
a highly potent strategy for expressing TRAIL because
tumors were more susceptible to TRAIL- induced apoptosis
when cocultured with TRAIL-expressing cells than when
directly transduced with the vector itself. Why transmem-
brane expression of TRAIL is so highly efficient for inducing
target cell apoptosis is unclear, although possibilities include
transmembrane TRAIL undergoing oligomerization at the
cell membrane following binding to its receptor on target
cells, target cell receptor oligomerization following engage-
ment of membrane bound TRAIL, and/or proper ligand/
receptor orientation and engagement. Although these
hypotheses need to be formally tested, such mechanisms
are consistent with the observed requirement for soluble
TRAIL oligomerization for full biologic activity.
We were surprised to find that direct vector-mediated
TRAIL transduction of tumor cells appears to be less efficient
at inducing apoptosis than by presentation by another cell.
Indeed, the surviving TRAIL- transduced tumor cells can
themselves act as efficient TRAIL-presenting cells and
mediate efficient cell death without dying themselves (Figure
2B ). The mechanisms behind this observation are also
unclear but may represent intracytoplasmic/ intragolgi
engagement of newly synthesized monomeric TRAIL mole-
cules with newly synthesized monomeric receptors given
that both are transmembrane proteins and are therefore
likely to end up in the same golgi / lysosomal transport
pathway. Such an intracellular interaction could inhibit proper
downstream signaling normally associated with TRAIL
receptor engagement. Further studies, however, will be
required for final determination of this potentially important
agonist /antagonist interaction.
Our data demonstrate that normal human primary cells
infected with an adenoviral vector encoding TRAIL were not
only viable, but also able to efficiently kill neighboring tumor
cells in vitro (Figure 2A ). TRAIL-mediated apoptosis may
function principally in a paracrine manner in vivo. A
paracrine mechanism of TRAIL-mediated cytotoxicity sug-
gests that normal cells infected with TRAIL can function as
‘‘TRAIL–effector cells in situ.’’ Therefore, tumor cells can be
killed not only by direct infection, but also by neighboring
cells ( i.e., bystander effect ). This may be particularly
important for the treatment of malignant brain tumors
because malignant glioma cells infiltrate deep within brain
parenchyma, intermixed with normal glial and neuronal
cells. It has been previously demonstrated that intracranial
injection of adenoviral vectors results in transduction of both
normal glial and neuronal cells in vivo, with prolonged
transgene expression (>2 months) [19]. Thus, adenoviral
transduction of TRAIL to normal brain tissue infiltrated by
glioma cells with the subsequent generation of a powerful
normal tissue-mediated tumor cell toxic bystander effect,
may offer distinct advantages for the treatment of malignant
gliomas over systemic delivery of the large recombinant
TRAIL protein. Such a approach is supported by our
demonstration that Ad.TRAIL-GFP–transduced NHA,
human neural progenitor cells and neurons show no signs
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of toxicity in vitro, yet can mediate an effective antiglioma
bystander effect (Figure 3 ).
Although theoretically attractive for gene therapy, the
clinical utility of adenoviral vectors may be limited by potent
antiviral immune responses directed against vector- trans-
duced cells. It has been well demonstrated that the initial
high- level transgene expression seen following adenoviral
vector transduction in vivo, diminishes to virtually nothing
within a few days in immunocompetent animals [29-31].
Given the recent demonstration that activated T lymphocytes
interacting with cells overexpressing TRAIL undergo apop-
tosis [31], we hypothesized that cells transduced by
adenoviral vectors expressing TRAIL may be less suscep-
tible to T cell–mediated cell death, thus allowing prolonged
transgene expression. Indeed, cellular FasL expression is
thought to be a major mechanisms responsible for the
downregulation of effector immune responses in immuno-
privileged areas of the body such as the brain, testes, and
eye [32], areas of the body where adenoviral vector–
mediated transgene expression is prolonged. Our data
demonstrate that adenoviral vectors that coexpress TRAIL,
can facilitate prolonged transgene expression in immuno-
competent animals by inhibiting the destruction of trans-
duced hepatocytes, thereby, in effect, creating a local area of
relative immune privilege (Figure 5 ). Vectors developed for
other gene therapy indications, where prolonged transgene
expression is optimal, may benefit from coexpression of
TRAIL.
In these studies, we have demonstrated the therapeu-
tic potential of an adenovirus-mediated in vivo trans-
duction strategy that combines the efficiency of adenoviral
gene transfer and the tumor-selective cytotoxicity of
TRAIL. We have demonstrated both the safety of a
TRAIL-expressing adenovirus in mice and its potent
antitumor effects in two different human xenograft tumor
models. Our data confirm recent studies demonstrating
tumor-specific cytotoxicity from various forms of recombi-
nant TRAIL proteins, and suggest gene transfer as a
potential alternative strategy for the efficient delivery of
TRAIL for localized malignant processes through the
generation of a potent, normal and tumor cell–mediated
bystander effect.
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